Dr. Min Cui is the Founder and Managing Director of Decheng Capital.
At Decheng Capital, Dr. Cui has been focusing on partnerships with entrepreneurs and building biotechnology and medical technology companies globally. He is currently a board member of Nuvation Bio (NASDAQ: NUVB), Baylor Genetics, Harton, Polares Medical, Mammoth Biosciences, Mirvie, Shape Therapeutics, Siro Diagnostics and Sunrise Oncology. He previously served on the boards of Alpine Immune Sciences (acquired by Vertex), ARMO BioSciences (acquired by Eli Lilly), China Biologic Products (NASDAQ: CBPO), Cirina (acquired by GRAIL), Cue Health (NASDAQ: HLTH), GeneWEAVE Biosciences (acquired by Roche), GenturaDx (acquired by Luminex), GRAIL (acquired by Illumina), ImmPACT Bio (acquired by Lyell Immunopharma), Ion Torrent Systems (acquired by Life Technologies), Sino Medical (688108.CH), and Velos Biopharma (acquired by Merck).
Prior to founding Decheng Capital in 2011, Dr. Cui spent 5 years at Bay City Capital, a leading international life science venture capital firm in San Francisco. He was previously an entrepreneur and started two biotech companies, following his PhD study in Cancer Biology at Stanford University. He also received his BS and MS in Molecular Biology from Peking University. Dr. Cui is currently a member of the board of trustees at Western University of Health Sciences.